Specialised Therapeutics, a biopharmaceutical company, has announced the approval of Zepzelca (lurbinectedin) in conjunction with atezolizumab (Tecentriq) as a first-line maintenance treatment for adults diagnosed with extensive-stage small cell lung cancer (ES-SCLC) in Australia and Singapore. This aggressive form of lung cancer often presents significant challenges due to its rapid progression and limited treatment options.
Approval Context
The approval follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use, which acknowledged Zepzelca’s potential in the European market. The combination of Zepzelca and atezolizumab has been recognized as an effective maintenance therapy for patients whose cancer has not advanced after initial treatment involving atezolizumab, carboplatin, and etoposide.
Both approvals were facilitated through Project Orbis, an initiative by the U.S. Food and Drug Administration’s Oncology Center of Excellence, aimed at expediting access to innovative cancer treatments. Since 2021, Specialised Therapeutics has successfully navigated this process eight times.
The Burden of Lung Cancer
Lung cancer poses a significant health issue in both Australia and Singapore. In Australia alone, around 15,000 individuals are diagnosed each year, with approximately 9,000 fatalities attributed to the disease. Singapore sees lung cancer as the third most common type of cancer, with nearly 9,732 new cases reported between 2019 and 2023. Small cell lung cancer accounts for about 10-15% of lung cancer cases and is often diagnosed at advanced stages, contributing to a grim five-year survival rate of less than 7%.
Expert Insights
Professor Nick Pavlakis, a medical oncologist at Royal North Shore Hospital in Sydney, emphasized the importance of this new treatment option. He noted that most patients with small cell lung cancer present with extensive-stage disease, facing high relapse rates and limited treatment avenues. The integration of immunotherapy into chemotherapy has improved patient outcomes over the past five years, but the clinical need for enhanced first-line treatments remains pressing.
A New Therapeutic Option
Carlo Montagner, CEO of Specialised Therapeutics, expressed enthusiasm about the approval of Zepzelca in combination with atezolizumab. He highlighted the significance of this new therapy, which offers an essential option for patients battling a challenging cancer type. Despite advancements in first-line therapies since 2019, many patients still experience relapse, necessitating second-line treatments. The availability of this new combination therapy aims to improve patient quality of life and extend time spent with loved ones.
PharmaMar’s Perspective
PharmaMar’s Chief Medical Officer, Javier Jimenez, welcomed the regulatory approval, recognizing it as a pivotal milestone in addressing the considerable unmet medical needs in lung cancer treatment. With a history of over 40 years dedicated to research in limited treatment areas, PharmaMar is committed to ensuring timely and equitable access to Zepzelca for patients in Australia and Singapore.
Mechanism of Action
Zepzelca belongs to the class of alkylating agents that function by damaging the DNA of cancer cells, effectively halting or slowing their proliferation. The approvals in Australia and Singapore were based on promising results from the phase 3 IMforte clinical trial, which involved 660 treatment-naïve patients across 13 countries. This trial demonstrated that the combination of Zepzelca and atezolizumab significantly outperformed atezolizumab alone in terms of both median progression-free survival (PFS) and overall survival (OS).
Clinical Trial Findings
In the IMforte trial, patients receiving the combination therapy exhibited a median PFS of 5.4 months compared to 2.1 months for those on atezolizumab alone. Additionally, median OS improved to 13.2 months versus 10.6 months, marking a notable advancement in treatment outcomes. While treatment-related adverse events were more prevalent in the combination group, the overall tolerability was deemed satisfactory, with no unexpected safety concerns arising.
Conclusion
The approval of Zepzelca combined with atezolizumab marks a significant advancement in the treatment landscape for extensive-stage small cell lung cancer. As new therapeutic options emerge, the hope is that they will translate into improved patient outcomes and quality of life. The ongoing commitment of Specialised Therapeutics and PharmaMar to address the challenges in cancer treatment exemplifies the potential for innovation in oncology.
- Key Takeaways:
- Zepzelca, in combination with atezolizumab, is now approved for ES-SCLC in Australia and Singapore.
- The combination therapy significantly improves both progression-free and overall survival rates.
- Ongoing research and innovation are essential to meet the pressing needs of lung cancer patients.
Read more → pharmabiz.com